galunisertib small molecular experimental cancer drug previously development eli lilly tgfb development galunisertib eli lilly discontinued january galunisertib investigated phase ii trial treatment hepatocellular preclinically combination galunisertib blockade resulted improved tumor growth httpsenwikipediaorgwikigalunisertib